NEW YORK (Reuters) – The enormous demand for weight-loss treatments like Novo Nordisk’s Wegovy could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. More than half a dozen companies, from…Read More
Novo Nordisk rivals see room to compete in 100 billion weightloss drug market By Reuters
